300 related articles for article (PubMed ID: 18040065)
1. Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
Bjelogrlic SK; Radic J; Radulovic S; Jokanovic M; Jovic V
Exp Biol Med (Maywood); 2007 Dec; 232(11):1414-24. PubMed ID: 18040065
[TBL] [Abstract][Full Text] [Related]
2. Activity of dexrazoxane and amifostine against late cardiotoxicity induced by the combination of doxorubicin and cyclophosphamide in vivo.
Bjelogrlic SK; Lukic ST; Djuricic SM
Basic Clin Pharmacol Toxicol; 2013 Oct; 113(4):228-38. PubMed ID: 23692343
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
Herman EH; Zhang J; Chadwick DP; Ferrans VJ
Cancer Chemother Pharmacol; 2000; 45(4):329-34. PubMed ID: 10755322
[TBL] [Abstract][Full Text] [Related]
4. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
Hofland KF; Thougaard AV; Sehested M; Jensen PB
Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
[TBL] [Abstract][Full Text] [Related]
5. Activity of d,l-alpha-tocopherol (vitamin E) against cardiotoxicity induced by doxorubicin and doxorubicin with cyclophosphamide in mice.
Bjelogrlic SK; Radic J; Jovic V; Radulovic S
Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):311-9. PubMed ID: 16236144
[TBL] [Abstract][Full Text] [Related]
6. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of saponins from Panax notoginseng against doxorubicin-induced cardiotoxicity in mice.
Liu L; Shi R; Shi Q; Cheng Y; Huo Y
Planta Med; 2008 Feb; 74(3):203-9. PubMed ID: 18260050
[TBL] [Abstract][Full Text] [Related]
8. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of selenium, WR-2721, and their combination in the prevention of adriamycin-induced cardiotoxicity in rats.
Dobrić S; Dragojević-Simić V; Bokonjić D; Milovanović S; Marincić D; Jović P
J Environ Pathol Toxicol Oncol; 1998; 17(3-4):291-9. PubMed ID: 9726805
[TBL] [Abstract][Full Text] [Related]
10. Amifostine and dexrazoxane enhance the rapid loss of bone mass and further deterioration of vertebrae architecture in female rats.
Mwale F; Ciobanu I; Demers CN; Antoniou J; Héon S; Servant N; Chalifour LE
Calcif Tissue Int; 2005 Sep; 77(3):175-9. PubMed ID: 16151678
[TBL] [Abstract][Full Text] [Related]
11. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR; Colan SD; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE
N Engl J Med; 2004 Jul; 351(2):145-53. PubMed ID: 15247354
[TBL] [Abstract][Full Text] [Related]
12. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
[TBL] [Abstract][Full Text] [Related]
14. Investigation of doxorubicin tissue toxicity: does amifostine provide chemoprotection? An experimental study.
Rigatos SK; Stathopoulos GP; Dontas I; Perrea-Kotsarelis D; Couris E; Karayannacos PE; Deliconstantinos G
Anticancer Res; 2002; 22(1A):129-34. PubMed ID: 12017274
[TBL] [Abstract][Full Text] [Related]
15. Amifostine protects against early but not late toxic effects of doxorubicin in infant rats.
Jahnukainen K; Jahnukainen T; Salmi TT; Svechnikov K; Eksborg S; Söder O
Cancer Res; 2001 Sep; 61(17):6423-7. PubMed ID: 11522636
[TBL] [Abstract][Full Text] [Related]
16. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
18. Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane.
Mladosievicova B; Foltinová A; Petrásová H; Bernadic M; Hulín I
Neoplasma; 2001; 48(1):61-5. PubMed ID: 11327539
[TBL] [Abstract][Full Text] [Related]
19. Cholinesterases in dexrazoxane-treated daunorubicin cardiomyopathy in rabbits.
Gersl V; Bajgar J; Hrdina R; Mazurová Y; Machácková J; Cerman J; Suba P
Gen Physiol Biophys; 1999 Dec; 18(4):335-46. PubMed ID: 10766032
[TBL] [Abstract][Full Text] [Related]
20. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Alderton P; Gross J; Green MD
Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
